Heron Therapeutics Inc. said it is planning to undertake an underwritten registered public offering of its common stock.
The San Diego-based biotechnology company said it intends to use the net proceeds for the commercial launch of HTX-011, if approved by the U.S. Food and Drug Administration, and further clinical studies of HTX-011, which is under investigation to reduce post-surgery pain.
Heron also plans to use the net proceeds for the continued commercialization of medicines - Cinvanti and Sustol, used to prevent acute and delayed chemotherapy-induced nausea and vomiting; for future clinical trials, other product development activities and general corporate purposes.
The company intends to grant the underwriters an option to buy up to an additional 15% of the shares sold in the offering.
Jefferies, Cowen and Evercore ISI are acting as joint book-running managers, while Cantor and JMP Securities are acting as lead managers for the offering. LifeSci Capital, Lake Street Capital Markets, National Securities Corp., Noble Capital Markets and Northland Capital Markets are each acting as co-managers for the offering.